Literature DB >> 1123493

Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrinsic asthma.

F G Buckle, A B Cohen.   

Abstract

This study was designed to test the hypothesis that patients with atopic rhinitis and extrinsic asthma have a nasal mucous membrane defect that allows inhaled macromolecules access to immunocompetent cells. Three groups were studied: normal subjects, patients with extrinsic asthma, and patients with atopic rhinitis. Albumin 125I(20 muc) was applied to the nasal mucosa and venous blood samples were drawn at set intervals up to 4 hours. Thirty-two minutes after administration, a significantly greater percentage of the dose was found in the plasma of patients with atopic rhinitis than in that of normal subjects (p smaller than 0.001). Transport of intact albumin across the nasal mucosa was demonstrated by dialysis, gel filtration, and immunopercipitation experiments in 3/9 normal subjects, 1/9 patients with asthma, and 9/10 patients with rhinitis (p smaller than 0.02). These studies suggest that large, potentially antigenic molecules pass more readily across the nasal mucous membrane of patients with allergic rhinitis than that of normal subjects. No increase in nasal transport was seen in patients with extrinsic asthma. It has not been determined whether this defect is a cause or an effect of atopic rhinitis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1123493     DOI: 10.1016/0091-6749(75)90139-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

1.  Local nasal specific immunotherapy for allergic rhinitis.

Authors:  Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Allergy Asthma Clin Immunol       Date:  2006-09-15       Impact factor: 3.406

2.  Effect of seasonal allergic rhinitis on airway mucosal absorption of chromium-51 labelled EDTA.

Authors:  L Greiff; P Wollmer; C Svensson; M Andersson; C G Persson
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

3.  Microvascular exudative hyperresponsiveness in human coronavirus-induced common cold.

Authors:  L Greiff; M Andersson; A Akerlund; P Wollmer; C Svensson; U Alkner; C G Persson
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

4.  Clinical and laboratory studies of the fate of intranasal allergen.

Authors:  Janet Rimmer; Conceição Santos; Eija Yli-Panula; Virginia Noronha; Markku Viander
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

Review 5.  Epithelial barriers in allergy and asthma.

Authors:  Peter W Hellings; Brecht Steelant
Journal:  J Allergy Clin Immunol       Date:  2020-06       Impact factor: 10.793

6.  Primary Nasal Epithelial Cells From Allergic and Non-allergic Individuals Show Comparable Barrier Function.

Authors:  Eva E Waltl; Victoria Stanek; Christian A Mueller; Renata Kiss; Julia Eckl-Dorna; Rudolf Valenta; Verena Niederberger
Journal:  Allergy Asthma Immunol Res       Date:  2020-03       Impact factor: 5.764

7.  Retinoic acid improves baseline barrier function and attenuates TNF-α-induced barrier leak in human bronchial epithelial cell culture model, 16HBE 14o.

Authors:  Patrick J Callaghan; Elizabeth Rybakovsky; Bryan Ferrick; Sunil Thomas; James M Mullin
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

8.  Nasal hyperreactivity and inflammation in allergic rhinitis.

Authors:  I M Garrelds; C de G Veld; R G Wijk; F J Zijlstra
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

Review 9.  Airway permeability.

Authors:  C G Persson; M Andersson; L Greiff; C Svensson; J S Erjefält; F Sundler; P Wollmer; U Alkner; I Erjefält; B Gustafsson
Journal:  Clin Exp Allergy       Date:  1995-09       Impact factor: 5.018

10.  Epithelial barrier function properties of the 16HBE14o- human bronchial epithelial cell culture model.

Authors:  Patrick J Callaghan; Bryan Ferrick; Elizabeth Rybakovsky; Sunil Thomas; James M Mullin
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.